203 related articles for article (PubMed ID: 36851662)
1. Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19.
Smith M; Kwatra G; Izu A; Nel A; Cutland C; Ahmed K; Baillie V; Barnabas S; Bhorat Q; Briner C; Lazarus E; Dheda K; Fairlie L; Koen A; Madhi S; Blackburn JM
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851662
[TBL] [Abstract][Full Text] [Related]
2. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study.
Tut G; Lancaster T; Krutikov M; Sylla P; Bone D; Kaur N; Spalkova E; Bentley C; Amin U; Jadir AT; Hulme S; Butler MS; Ayodele M; Bruton R; Shrotri M; Azmi B; Fuller C; Irwin-Singer A; Hayward A; Copas A; Shallcross L; Moss P
Lancet Healthy Longev; 2021 Sep; 2(9):e544-e553. PubMed ID: 34430954
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
Front Immunol; 2022; 13():811020. PubMed ID: 35126395
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
[TBL] [Abstract][Full Text] [Related]
5. IgG antibody levels against the SARS-CoV-2 spike protein in mother-child dyads after COVID-19 vaccination.
Muñoz-Gómez MJ; Martin-Vicente M; Vigil-Vazquez S; Carrasco I; Lobo AH; Mas V; Vázquez M; Manzanares A; Cano O; Zamora C; Alonso R; Sepulveda-Crespo D; Tarancon-Diez L; Muñoz-Fernández MÁ; Muñoz-Chapuli M; Resino S; Navarro ML; Martinez I
Infection; 2024 Jun; 52(3):813-824. PubMed ID: 37898587
[TBL] [Abstract][Full Text] [Related]
6. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
[TBL] [Abstract][Full Text] [Related]
7. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study.
Selma-Royo M; Bäuerl C; Mena-Tudela D; Aguilar-Camprubí L; Pérez-Cano FJ; Parra-Llorca A; Lerin C; Martínez-Costa C; Collado MC
Genome Med; 2022 Apr; 14(1):42. PubMed ID: 35449030
[TBL] [Abstract][Full Text] [Related]
8. Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination.
Motsoeneng BM; Manamela NP; Kaldine H; Kgagudi P; Hermanus T; Ayres F; Makhado Z; Moyo-Gwete T; van der Mescht MA; Abdullah F; Boswell MT; Ueckermann V; Rossouw TM; Madhi SA; Moore PL; Richardson SI
Front Immunol; 2023; 14():1231276. PubMed ID: 37600825
[TBL] [Abstract][Full Text] [Related]
9. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
[TBL] [Abstract][Full Text] [Related]
10. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
11. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE
Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547
[TBL] [Abstract][Full Text] [Related]
12. Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals.
Patil R; Shanbhag S; Shankarkumar A; Madkaikar M
Indian J Med Res; 2022; 155(5&6):538-545. PubMed ID: 36124500
[TBL] [Abstract][Full Text] [Related]
13. mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals.
Longet S; Hargreaves A; Healy S; Brown R; Hornsby HR; Meardon N; Tipton T; Barnes E; Dunachie S; Duncan CJA; Klenerman P; Richter A; Turtle L; de Silva TI; Carroll MW
Front Immunol; 2022; 13():953949. PubMed ID: 36159846
[TBL] [Abstract][Full Text] [Related]
14. Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study.
Søgaard OS; Reekie J; Johansen IS; Nielsen H; Benfield T; Wiese L; Stærke NB; Iversen K; Fogh K; Bodilsen J; Iversen M; Knudsen LS; Klastrup V; Larsen FD; Andersen SD; Hvidt AK; Andreasen SR; Madsen LW; Lindvig SO; Øvrehus A; Ostrowski SR; Abildgaard C; Matthews C; Jensen TO; Raben D; Erikstrup C; Fischer TK; Tolstrup M; Østergaard L; Lundgren J;
Clin Microbiol Infect; 2022 Aug; 28(8):1126-1133. PubMed ID: 35283313
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 RBD-Specific Antibodies Induced Early in the Pandemic by Natural Infection and Vaccination Display Cross-Variant Binding and Inhibition.
Walker MR; Podlekareva D; Johnsen S; Leerhøy B; Fougeroux C; Søgaard M; Salanti A; Ditlev SB; Barfod L
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146667
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
[TBL] [Abstract][Full Text] [Related]
17. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
[TBL] [Abstract][Full Text] [Related]
18. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
19. A study on seroconversion following first & second doses of ChAdOx1 nCoV-19 vaccine in Central Kerala.
Varghese SM; Mateethra GC; George G; Chandran VS; John GM; Varghese LT; Mammen NK; Vinayak V
Indian J Med Res; 2022; 155(5&6):499-504. PubMed ID: 36348597
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of SARS-CoV-2 Spike-IgG throughout Three COVID-19 Vaccination Regimens: A 21-Month Longitudinal Study of 82 Norwegian Healthcare Workers.
Augustinussen MH; Tylden GD; Rinaldo CH
Viruses; 2023 Feb; 15(3):. PubMed ID: 36992328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
